Abstract
lesions. Since then, over 300 cases have been studied. Recently, for unresectable cases, we employed the mediastinoscopic and thoracoscopic surgery to obtain the biopsy specimens for the chemosensitivity test. Twenty unresectable lung cancer patients including 19 non-small cell lung cancer and 1 small cell lung cancer underwent endoscopic surgery in our institute. Biopsy specimens were obtained 5 from primary lesions, 14 from metastatic lymphnodes, and 1 from lung metastasis, and were applied to the chemosensitivity test. We performed the chemosensitivity test by the formazan-based MTT assay (Histoculture Drug Response Assay; HDRA) with CDDP, 5-FU, ADM, MMC, VP-16, DOC, PAC, SN38 and GEM. The inhibition rate was applied to evaluate drug sensitivity. An average of 612 (2-9) drugs was tested using these specimens in each patient. There was no sensitive drug in 4 patient. One patient refused the chemotherapy. Chemotherapy including sensitive drugs was performed in the other 15 patients. The response rate of 92% (11 PR and 1 NC) was observed among 12 evaluable patients. Median survival of 27 months was obtained during 16f9 (5-32) months follow-up. [Conclusion] We could obtain sufficient dose of specimens for HDRA by endoscopic surgery. Good response rate was observed in patients with chemotherapy using HDRA sensitive agents,
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
